Chief Executive Officer
Mr. Ng is a seasoned life sciences industry executive. He previously was Board Director, President & Chief Operating Officer at Calidi Biotherapeutics, Inc. Mr. Ng is also a partner at PENG Life Science Ventures (PENG LSV). He has founded and/or led multiple companies, including Scilex Pharmaceuticals, Inc. (now, Scilex Holding Co (NASDAQ:SCLX)), where he was Co-Founder and President, and led the company through development, clinical trials, NDA submission, FDA approval, $140 million financing, commercial launch of the company’s first FDA-approved drug product, and ultimate company sale. Mr. Ng has also held various other senior management positions, including Board Director, Managing Director, Chief Administrative Officer, Chief Business Officer, Corporate Secretary, Chief Legal Officer, General Counsel, Chief Compliance Officer and Chief Intellectual Property Counsel, with publicly-traded and private, global biotechnology and pharmaceutical companies, including Sorrento Therapeutics, Inc. (NASDAQ: SRNE), BioDelivery Sciences International, Inc. (NASDAQ: BDSI), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and Alpharma, Inc. (NYSE:ALO), which is now, a part of Pfizer Inc. In these roles, Mr. Ng helped lead the strategy, development, fundraising and commercialization efforts and launches of multiple pharmaceutical drug products. Previously, in private practice, Mr. Ng was a partner in two AMLAW 200 law firms, where he had leadership roles, including establishing the life sciences practice group for one firm and heading it as the national co-chair. Additionally, Mr. Ng is a past and current member of the Board of Directors for multiple companies, including Iacta Pharmaceuticals, Inc., Morphogenesis, Inc., and Calidi Biotherapeutics, Inc.
Mr. Ng was also a past President-Elect of the Pan Asian Lawyers of San Diego (PALSD) and was previously appointed to the Leadership Development Committee of the Wake County Bar Association in North Carolina. In addition, he is a frequent speaker and noted authority on business, legal, compliance and regulatory issues in the life sciences, with past speaking engagements at the 2011 BIO International Convention and various pharmaceutical, legal and compliance congresses and conferences. Among his multiple awards and commendations, Mr. Ng is a recipient of the 2015 Outstanding 50 Asian Americans in Business Award, past recipient of M&A Advisor’s Top 40 Under 40 Award (in 2012) and nominee for the Orange County Business Journal’s Inaugural General Counsel Awards (in 2010); and, in 2010, MDB Capital recognized Mr. Ng (and the company where he led the intellectual property efforts) for its Best and Brightest Award and as an Astrum Award nominee for a pharmaceutical patent portfolio that he managed and developed.
Mr. Ng earned a Juris Doctor (J.D.) degree in law from the University of Notre Dame School of Law and a Bachelor of Arts and Sciences (B.A.S.) dual degree in Biochemistry & Economics from the University of California, Davis.